(Source: Bioalliance Pharma SA) This document may not be published, distributed or disseminated, directly or indirectly,in the United States of America, Canada, Australia or Japan. BioAlliance Pharma announces a successful capital increase • Total gross amount to be raised : 8,7 million euros • transaction over-subscribed of 155% • Implementation of the extension clause Paris, July 19, 2013 - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and supportive care products, announces a successful capital increase, with maintenance of preferential subscription rights, launched on July 2, 2013, and which will enable the...
↧